Inhibiting a particular protein in cancer-killing immune cells might improve the long-term effectiveness of CAR T cell and other immune checkpoint therapies, according to a study by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Intermountain Health is now offering a national expansion of CAR-T cell therapy, bringing cancer care closer to patients in southern Utah and Nevada.
